A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment

Abstract

Cutaneous lupus erythematosus is a previously undiagnosed side-effect of ranibizumab. Here, we present a case of an 82-year-old female Caucasian patient with wet age-related macular degeneration. Following a single intraocular injection of Lucentis (ranibizumab), she developed a subacute cutaneous lupus erythematosus which, with treatment, took nearly 12 months to resolve. This shows that cutaneous lupus erythematosus is a potential side-effect of many medications, including ranibizumab, as in our case and, in an aging population where polypharmacy is a growing reality, clinicians should be aware of how to diagnose and best manage such cases.

Keywords

• Amblyopia
• nasolacrimal duct obstruction
• probing
• Duane syndrome
• esotropia
• strabismus
• Bevacizumab
• mitochondrial function
• microvascular endothelial cells
• neurosensory retinal cells
• retinal pigment epithelial cells
• tissue culture
• Clinical donor tissue grading
• death to enucleation time
• death to preservation time
• eye bank specular microscopy
• optimizing donor tissue utilization
• DCR
• endodiathermy bipolar probe
• nasolacrimal duct obstruction
• recanalize
• Age-related macular degeneration
• carotenoids
• cross-sectional studies
• lutein
• Children
• GDx variable corneal compensation
• Indian
• normal
• retinal nerve fiber layer thickness
• Biological amniotic membrane
• 5-fluorouracil
• retina
• trabeculectomy
• Clinical features
• complications
• etiology
• retinal vasculitis
• Thailand
• Coloboma of the choroid
• coloboma optic disc
• indo cyanine green angiography
• vascular pattern
• Aphakia
• inadequate capsular support
• pediatric aphakia
• secondary intraocular lens implantation
• steel suture
• trans-scleral fixation
• vanadium steel
• Drug reaction
• drug-induced
• ranibizumab
• subacute cutaneous lupus erythematosus